Cada Michaela, Segbefia Catherin I, Klaassen Robert, Fernandez Conrad V, Yanofsky Rochelle A, Wu John, Pastore Yves, Silva Mariana, Lipton Jeffrey H, Brossard Josee, Michon Bruno, Abish Sharon, Steele MacGregor, Sinha Roona, Belletrutti Mark, Breakey Vicky, Jardine Lawrence, Goodyear Lisa, Sung Lillian, Shago Mary, Beyene Joseph, Sharma Preeti, Zlateska Bozana, Dror Yigal
Marrow Failure and Myelodysplasia Program, Division of Haematology/Oncology, Department of Paediatrics and the Genetics and Genome Biology Program, Research Institute, The Hospital for Sick Children and the University of Toronto, Ontario, Canada.
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
Haematologica. 2015 May;100(5):633-42. doi: 10.3324/haematol.2014.117457. Epub 2015 Feb 14.
Inherited bone marrow failure syndromes are a group of rare, heterogeneous genetic disorders with a risk of clonal and malignant myeloid transformation including clonal marrow cytogenetic abnormalities, myelodysplastic syndrome and acute myeloid leukemia. The clinical characteristics, risk classification, prognostic factors and outcome of clonal and malignant myeloid transformation associated with inherited bone marrow failure syndromes are largely unknown. The aims of this study were to determine the impact of category, cytopathology and cytogenetics, the three components of the "Category Cytology Cytogenetics" classification of pediatric myelodysplastic syndrome, on the outcome of clonal and malignant myeloid transformation associated with inherited bone marrow failure. We used data from the Canadian Inherited Marrow Failure Registry. Among 327 patients with inherited bone marrow failure syndrome enrolled in the registry, the estimated risk of clonal and malignant myeloid transformation by the age of 18 years was 37%. The risk of clonal and malignant myeloid transformation varied according to the type of inherited bone marrow failure syndrome but was highest in Fanconi anemia. The development of clonal and malignant myeloid transformation significantly affected overall survival. Mortality varied based on cytopathological group. The largest group of patients had refractory cytopenia. Clonal marrow cytogenetic abnormalities were identified in 87% of patients with clonal and malignant myeloid transformation, and different cytogenetic groups had different impacts on disease progression. We conclude that category, cytopathology and cytogenetics in cases of clonal and malignant myeloid transformation associated with inherited bone marrow failure syndromes have an important impact on outcome and that the classification of such cases should incorporate these factors.
遗传性骨髓衰竭综合征是一组罕见的、异质性的遗传疾病,存在克隆性和恶性髓系转化风险,包括克隆性骨髓细胞遗传学异常、骨髓增生异常综合征和急性髓系白血病。与遗传性骨髓衰竭综合征相关的克隆性和恶性髓系转化的临床特征、风险分类、预后因素及结局在很大程度上尚不清楚。本研究的目的是确定儿童骨髓增生异常综合征“类别-细胞学-细胞遗传学”分类的三个组成部分,即类别、细胞病理学和细胞遗传学,对与遗传性骨髓衰竭相关的克隆性和恶性髓系转化结局的影响。我们使用了加拿大遗传性骨髓衰竭登记处的数据。在登记处登记的327例遗传性骨髓衰竭综合征患者中,18岁时克隆性和恶性髓系转化的估计风险为37%。克隆性和恶性髓系转化的风险因遗传性骨髓衰竭综合征类型而异,但在范可尼贫血中最高。克隆性和恶性髓系转化的发生显著影响总生存期。死亡率因细胞病理学组而异。最大的患者群体为难治性血细胞减少症。在87%的克隆性和恶性髓系转化患者中发现了克隆性骨髓细胞遗传学异常,不同的细胞遗传学组对疾病进展有不同影响。我们得出结论,与遗传性骨髓衰竭综合征相关的克隆性和恶性髓系转化病例中的类别、细胞病理学和细胞遗传学对结局有重要影响,此类病例的分类应纳入这些因素。